Skip To Main Content
Vianney Baris on Muck Rack

Vianney Baris

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vianney

Contact Vianney, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial - Nature Medicine

|
By Fernanda Mosele, Elise Deluche, Barbara Pistilli, Thomas Bachelot, Nathalie Droin, Maki Kobayashi, Marc Deloger, Marta Jiménez, Patricia L. Kannouche, Magali Lacroix-Triki, Véronique Diéras, Yoann Pradat, Ingrid Judith Garberis, Stergios Christodoulidis, Celine Mahier, Vianney Baris, Virginie Marty
| Nature Verified
Abstract The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial evaluated the efficacy of T-DXd in patients with HER2-overexpressing (n = 72, cohort 1), HER2-low (n = 74, cohort 2) and HER2 non-expressing (n = 40, cohort 3) metastatic breast cancer.
Open in Who Shared Issue with article?
See all 1 articles